If type 2 diabetes is a clinical state of inflammation with high levels of cytokines such as TNFα [9–11, 39–41] and these levels can be reduced by certain anti-inflammatory drugs [2, 3], why these cannot be used as another component of our treatment strategy for this common disease? Here, TNF is linked to type 2 diabetes mellitus.